612 related articles for article (PubMed ID: 8640334)
21. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice.
Teng CM; Wu CC; Ko FN; Lee FY; Kuo SC
Eur J Pharmacol; 1997 Feb; 320(2-3):161-6. PubMed ID: 9059849
[TBL] [Abstract][Full Text] [Related]
22. Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1.
Nakane M; Hsieh G; Miller LN; Chang R; Terranova MA; Moreland RB; Kolasa T; Brioni JD
Int J Impot Res; 2002 Apr; 14(2):121-7. PubMed ID: 11979328
[TBL] [Abstract][Full Text] [Related]
23. Antiplatelet effect of marchantinquinone, isolated from Reboulia hemisphaerica, in rabbit washed platelets.
Liao CH; Ko FN; Wu CL; Teng CM
J Pharm Pharmacol; 2000 Mar; 52(3):353-9. PubMed ID: 10757426
[TBL] [Abstract][Full Text] [Related]
24. Antithrombotic effects of peroxynitrite: inhibition and reversal of aggregation in human platelets.
Yin K; Lai PS; Rodriguez A; Spur BW; Wong PY
Prostaglandins; 1995 Sep; 50(3):169-78. PubMed ID: 8750213
[TBL] [Abstract][Full Text] [Related]
25. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
26. Autoregulation of nitric oxide-soluble guanylate cyclase-cyclic GMP signalling in mouse thoracic aorta.
Hussain MB; Hobbs AJ; MacAllister RJ
Br J Pharmacol; 1999 Nov; 128(5):1082-8. PubMed ID: 10556946
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate.
Homer KL; Wanstall JC
Br J Pharmacol; 2002 Dec; 137(7):1071-81. PubMed ID: 12429580
[TBL] [Abstract][Full Text] [Related]
28. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin.
Chou TC; Lin YF; Wu WC; Chu KM
Br J Pharmacol; 2008 Mar; 153(6):1281-7. PubMed ID: 18264124
[TBL] [Abstract][Full Text] [Related]
29. Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway.
Hwang TL; Hung HW; Kao SH; Teng CM; Wu CC; Cheng SJ
Mol Pharmacol; 2003 Dec; 64(6):1419-27. PubMed ID: 14645672
[TBL] [Abstract][Full Text] [Related]
30. Exogenous GTP increases cyclic GMP and inhibits thrombin-induced aggregation of washed human platelets: comparison with ATP, adenosine and guanosine.
Vuorinen P; Laustiola KE
Pharmacol Toxicol; 1992 Oct; 71(4):289-93. PubMed ID: 1333596
[TBL] [Abstract][Full Text] [Related]
31. Nitric oxide donors induce extrusion of cyclic GMP from isolated human blood platelets by a mechanism which may be modulated by prostaglandins.
Radziszewski W; Chopra M; Zembowicz A; Gryglewski R; Ignarro LJ; Chaudhuri G
Int J Cardiol; 1995 Oct; 51(3):211-20. PubMed ID: 8586470
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of human platelet aggregation by S-nitrosothiols. Heme-dependent activation of soluble guanylate cyclase and stimulation of cyclic GMP accumulation.
Mellion BT; Ignarro LJ; Myers CB; Ohlstein EH; Ballot BA; Hyman AL; Kadowitz PJ
Mol Pharmacol; 1983 May; 23(3):653-64. PubMed ID: 6135148
[TBL] [Abstract][Full Text] [Related]
33. Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibalpha glycoprotein.
Ferreira MA; do Nascimento NR; de Sousa CM; Pessoa OD; de Lemos TL; Ventura JS; Schattner M; Chudzinski-Tavassi AM
Br J Pharmacol; 2008 Jul; 154(6):1216-24. PubMed ID: 18516074
[TBL] [Abstract][Full Text] [Related]
34. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function.
Murray KJ; England PJ; Hallam TJ; Maguire J; Moores K; Reeves ML; Simpson AW; Rink TJ
Br J Pharmacol; 1990 Mar; 99(3):612-6. PubMed ID: 2158847
[TBL] [Abstract][Full Text] [Related]
35. Involvement of protein kinase C in reduced relaxant responses to the NO/cyclic GMP pathway in piglet pulmonary arteries contracted by the thromboxane A2-mimetic U46619.
Pérez-Vizcaíno F; Villamor E; Duarte J; Tamargo J
Br J Pharmacol; 1997 Aug; 121(7):1323-33. PubMed ID: 9257910
[TBL] [Abstract][Full Text] [Related]
36. Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production.
Jeng JH; Wu HL; Lin BR; Lan WH; Chang HH; Ho YS; Lee PH; Wang YJ; Wang JS; Chen YJ; Chang MC
Atherosclerosis; 2007 Apr; 191(2):250-8. PubMed ID: 16797553
[TBL] [Abstract][Full Text] [Related]
37. Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway.
Hwang TL; Wu CC; Guh JH; Teng CM
Biochem Pharmacol; 2003 Jul; 66(1):149-56. PubMed ID: 12818375
[TBL] [Abstract][Full Text] [Related]
38. Contractile responses to sumatriptan in isolated bovine pulmonary artery rings: relationship to tone and cyclic nucleotide levels.
Sweeney G; Templeton A; Clayton RA; Baird M; Sheridan S; Johnston ED; MacLean MR
J Cardiovasc Pharmacol; 1995 Nov; 26(5):751-60. PubMed ID: 8637190
[TBL] [Abstract][Full Text] [Related]
39. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
Vezza R; Nenci GG; Gresele P
J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
